MUSC Cardiology
Avatar

Mechanisms of Diastolic Dysfunction (Fibrosis, Myofilaments, etc) and How to Make Them Therapeutic Targets

By MUSC Cardiology FEATURING Michael Zile
By MUSC Cardiology FEATURING Michael Zile
40 views
September 14, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

48:22
Lilly Diabetes

A Journey Through Clinical Efficacy and Safety Data Comparing Two T2…

Feat. B. Hirsch

Featured Video

48:22
Lilly Diabetes

A Journey Through Clinical Efficacy and Safety Data Comparing Two T2…

Feat. B. Hirsch

Related Content

AUTOPLAY
Medical College of Georgia - Augusta University

Cardiovascular Summit at Kiawah 2024

Thu, Jul 18, 2024
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
15:47
Scripps Health

HFpEF in Women

Feat. B. Borlaug
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
29:08
Scripps Health

Case Presentation: Complex PCI with IABP

Feat. R. Khedraki, T. Heywood, R. Mohan, A. Srivastava
17:08
CVRx | Barostim

Integrating Barostim into a Comprehensive Heart Failure Program ISHL…

Feat. D. Yaranov, P. Patel, R. Gupta, J. Schmitto, E. Chung
35:16
Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson
17:42
Scripps Health

Heart Failure with Preserved Ejection Fraction: New Treatments - 202…

Feat. R. C. Mohan
12:09
ARCH Advanced Revascularization Symposium

End-Stage Heart Failure Therapies

Feat. D. Horstmanshof
17:29
UCLA Health

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

Feat. D. Vucicevic
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim
14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
17:22
Samuel Sherratt

Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Has High Membrane Affi…